AstraZeneca Zoladex

Zoladex, known scientifically as goserelin acetate, is an injectable luteinizing hormone-releasing hormone (LHRH) agonist. It was originally researched and developed by Imperial Chemical Industries (ICI) Pharmaceuticals in the United Kingdom during the late 1970s and 1980s.

Following the demerger of ICI's pharmaceutical business into Zeneca Group PLC and the subsequent 1999 merger with Swedish Astra AB, the brand became a cornerstone of the AstraZeneca oncology portfolio. Today, the product is primarily manufactured at AstraZeneca's specialized facility in Macclesfield, England, which serves as a global hub for the production of these complex injectable depots.

While AstraZeneca retains the manufacturing and core ownership rights in many global markets, strategic partnerships have been formed in specific regions for distribution and promotion. The brand represents a significant legacy in British biotechnology and remains a vital treatment in the management of prostate cancer and breast cancer worldwide.